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The Human Immunodeficiency Virus type 1 (HIV-1) accessory protein Vpr enhances viral 33 
replication in both macrophages and in cycling T cells to a lesser extent. Virion packaged Vpr is 34 
released in target cells shortly after entry, suggesting its requirement in the early phase of infection. 35 
Previously, we described REAF (RNA-associated Early-stage Antiviral Factor, RPRD2), a 36 
constitutively expressed protein that potently restricts HIV replication at or during reverse 37 
transcription. Here, we show that a virus without intact vpr is more highly restricted by REAF and, 38 
using delivery by VLPs, that Vpr alone is sufficient for REAF degradation in primary 39 
macrophages.  REAF is more highly expressed in macrophages than in cycling T cells and we 40 
detect, by co-immunoprecipitation assay, an interaction between Vpr protein and endogenous 41 
REAF. Vpr acts very quickly during the early phase of replication and induces the degradation of 42 
REAF within 30 minutes of viral entry. Using Vpr F34I and Q65R viral mutants, we show that 43 
nuclear localisation and interaction with cullin4A-DBB1 (DCAF1) E3 ubiquitin ligase is required 44 
for REAF degradation by Vpr. In response to infection, cells upregulate REAF levels. This 45 
response is curtailed in the presence of Vpr. These findings support the hypothesis that Vpr induces 46 
the degradation of a factor, REAF, which impedes HIV infection in macrophages. 47 
  48 
Importance  49 
For at least 30 years, it has been known that HIV-1 Vpr, a protein carried in the virion, is 50 
important for efficient infection of primary macrophages. Vpr is also a determinant of the 51 
pathogenic effects of HIV-1 in vivo. A number of cellular proteins that interact with Vpr have been 52 
identified. So far, it has not been possible to associate these proteins with altered viral replication 53 
in macrophages, or to explain why Vpr is carried in the virus particle. Here we show that Vpr 54 
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mitigates the antiviral effects of REAF, a protein highly expressed in primary macrophages and 55 
one which inhibits virus replication early during reverse transcription. REAF is degraded by Vpr 56 
within 30 minutes of virus entry, in a manner dependent on the nuclear localization of Vpr and its 57 




















Human Immunodeficiency Virus type 1 (HIV-1) infects CD4+ T cells and macrophages in 76 
vivo.  HIV-1 has four non-structural accessory genes nef, vif, vpu and vpr. Nef, vif and vpu diminish 77 
host innate immunity. A function for Vpr has been elusive, but it is required for efficient replication 78 
in macrophages and for pathogenesis in vivo (1, 2). A widely acknowledged but poorly understood 79 
Vpr-mediated phenotype is that it induces cell cycle arrest at the G2/M phase using the cullin4A-80 
DBB1 (DCAF1) E3 ubiquitin ligase and the recruitment of an unknown substrate for proteasomal 81 
degradation. A large number of Vpr substrates have been reported (3-11). Yan et al. (2019) show 82 
that helicase-like transcription factor (HLTF) weakly restricts replication of HIV-1 in T cells. 83 
HLTF was shown previously to be down modulated by Vpr (12, 13). Furthermore, Greenwood et 84 
al. 2019 report that Vpr promotes large- scale remodelling of approximately 2000 cellular proteins, 85 
including those that bind nucleic acids and ones involved with the cell cycle (14). 86 
Substantial quantities of Vpr are incorporated into viral particles and released from the 87 
major capsid protein (CA) after entry into the cell (15, 16).  The timing of Vpr release coincides 88 
with the initiation of reverse transcription, a process that transcribes the RNA genome into DNA 89 
for subsequent integration into the host cell DNA (17). The early release of Vpr from the CA 90 
implies it has an early function prior to integration events. When considering the role of Vpr in 91 
cell tropism and pathogenesis, the investigation of proteins that have a direct effect on viral 92 
replication is a priority.   93 
Here we focus on RNA-associated Early-stage Antiviral Factor (REAF, also known as 94 
Regulation of nuclear pre-mRNA domain-containing protein 2/RPRD2), originally described as a 95 
restriction to HIV replication and called lentiviral restriction 2 (Lv2) (18, 19). Lv2 was first shown 96 
to be a restriction to the replication of HIV-2 and subsequently it was shown to inhibit the 97 
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replication of HIV-1 and SIV during reverse transcription (20). Lv2/REAF restriction is cell type 98 
dependent (19, 21-24), active in certain cell types including HeLa-CD4 and primary macrophages 99 
(18, 19). Susceptibility of the virus to Lv2 is determined by both the viral envelope (Env) and 100 
capsid (CA) (23, 24). REAF was identified in a whole genome siRNA screen for the identification 101 
of HIV-1 restriction factors. Like Lv2, REAF limits the completion of proviral DNA synthesis and 102 
integration of the viral genome (18).  Subsequently, REAF was demonstrated to form a major 103 
component of Lv2 (19). 104 
 Here, we show that within 30 minutes of cellular entry, only HIV-1 virus that contains Vpr 105 
can induce the degradation of REAF and rescue efficient viral replication in primary macrophages. 106 
Using Vpr mutant viruses, we demonstrate that the nuclear localisation of Vpr, and its ability to 107 
interact with cullin4A-DBB1 (DCAF1) E3 ubiquitin ligase, is a requirement for REAF 108 
degradation. Down modulation of REAF by Vpr in the early phase of infection is transient and re-109 
expression to basal levels is achieved by approximately one hour. After infection with HIV-1, or 110 
treatment with polyriboinosinic:polyribocytidylic acid (poly(I:C)) or Lipopolysaccharide (LPS), 111 
cells respond by increasing REAF levels. In the case of viral infection, this response is curtailed 112 
in the presence of Vpr. Therefore, our results support the hypothesis that Vpr induces the 113 
degradation of a cellular protein, REAF, a protein which impedes HIV-1 infection in macrophages 114 









HIV-1 Vpr interacts with REAF and overcomes restriction.  122 
REAF restricts HIV-1 replication in HeLa-CD4 (18, 20). We sought to determine if a viral 123 
accessory gene could overcome REAF and so we tested the infectivity of HIV-1 89.6WT and 124 
mutants deleted for vpr (89.6Δvpr), vif (89.6Δvif) or vpu (89.6Δvpu) in these cells. Preventing REAF 125 
expression using short-hairpin RNA (HeLa-CD4 shRNA-REAF, Figure 1A) reveals its potent 126 
antiviral effect.  Despite a standard input for each virus (50 FFU/ml, as measured on HeLa-CD4), 127 
there is significantly greater rescue of HIV-1 89.6Δvpr (>3 fold, p < 0.0001) compared to HIV-1 128 
89.6WT (Figure 1B). The prevention of REAF expression using shRNA alleviates the need for Vpr. 129 
Conversely, there was no significantly greater rescue for either HIV-1 89.6Δvif or HIV-1 89.6Δvpu 130 
compared to HIV-1 89.6WT (data not shown). Thus, vpr potently overcomes the restriction imposed 131 
by REAF.  132 
 We are unaware of previous reports that Vpr overcomes known or unknown HIV-1 133 
restrictions in HeLa-CD4. Therefore, we confirmed that the mutant HIV-1 89.6Δvpr is restricted in 134 
HeLa-CD4 compared to HIV-1 89.6WT. Figure 1C shows that despite equal viral inputs (measured 135 
by ELISA of viral protein p24), significantly fewer foci of infection (FFU) result from challenge 136 
with HIV-1 89.6Δvpr compared to HIV-1 89.6WT. Further support of a role for Vpr in overcoming 137 
REAF is evidenced in Figure 1D. When HeLa-CD4 are challenged with a HIV-1 89.6WT (which 138 
has an intact vpr), REAF protein is down modulated. The observed down modulation is dependent 139 
on the presence of Vpr as HIV-1 89.6∆vpr is incapable of degrading REAF. Moreover, Figure 1E 140 
shows that Vpr and REAF interact with each other, either directly or indirectly as part of a 141 
complex, as they are co-immunoprecipitated.  142 
Vpr is released from the capsid and enters the nucleus shortly after infection (11). Imaging 143 
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flow cytometry combines traditional flow cytometry with microscopy, facilitating the evaluation 144 
of both the expression and subcellular localisation of proteins in large populations of cells (25, 26). 145 
Using imaging flow cytometry, we determined the relative subcellular localization of REAF in 146 
HeLa-CD4. This analysis reveals that REAF is more highly expressed in the nuclear region 147 
compared to the cytoplasmic region of cycling HeLa-CD4 (Figure 1F).  148 
Previously, we reported that REAF affects the production of reverse transcripts early in 149 
infection and that at this critical time point, REAF is transiently down modulated in HeLa-CD4 150 
(20). Also using image flow cytometry, we looked the subcellular distribution of REAF at the early 151 
time points following HIV-1 infection. Here, REAF protein was quantified by imaging flow 152 
cytometry in the cytoplasm and nucleus of HeLa-CD4 over the  first 3 hours of infection with 153 
either HIV-1 89.6WT or HIV-1 89.6Δvpr. Following challenge with HIV-1 89.6Δvpr, REAF levels 154 
increase within 0.5 hours in both the nucleus (~25%, Figure 1G, left) and cytoplasm (~10%, Figure 155 
1G, right). Nuclear levels remain high for 3 hours. Conversely, in the presence of Vpr (HIV-1 156 
89.6WT) this increase in REAF is curtailed, instead there is a steady decline from 0.5-2 hours. The 157 
decline is most apparent in the nucleus with ~20% reduction by 1 hour and ~30% at 2 hours. By 3 158 
hours, levels of REAF protein recover. The virus carries limited quantities of Vpr (17), which 159 
potentially explains why there is a pause in REAF down modulation. Lower levels of REAF were 160 
also observed in the cytoplasm over time after infection with HIV-1 89.6WT, but to a much lesser 161 
extent (Figure 1G, right). The nuclear enrichment score (NES) is a comparison of the intensity of 162 
REAF fluorescence inside the nucleus (defined using DAPI) to the total fluorescence intensity of 163 
REAF in the entire cell (defined using brightfield images). The lower the score, the less REAF in 164 
the nucleus relative to in the cell overall. Imaging flow cytometry software determined the NES 165 
over time after infection with HIV-1 89.6WT or HIV-1 89.6∆vpr (Figure 1H). By 1-2 hours, a 166 
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significant segregation emerges; in the presence of Vpr relative nuclear levels of REAF are 167 
suppressed. The greatest segregation occurs 2 hours post-infection. 168 
 169 
Fluctuations in subcellular REAF expression after HIV-1 infection are Vpr dependent. 170 
Macrophages are a target for HIV infection in vivo (27). Vpr has been shown, to varying 171 
degrees, to be more beneficial for replication in these cells than in cycling T cells (28-32). For that 172 
reason, we investigated REAF effects in monocyte-derived macrophages (MDMs). Also using 173 
imaging flow cytometry, we determined that similar to HeLa-CD4, MDMs have significantly 174 
greater quantities of REAF in the nucleus compared to in the cytoplasm (Figure 2A). Nuclear 175 
levels of REAF were also compared in a number of primary cell types using imaging flow 176 
cytometry (Figure 2B). When compared with either monocytes or resting/activated T cells, both 177 
MDMs and dendritic cells (DCs) highly express nuclear REAF. In Figure 2C, MDMs were treated 178 
with virus-like particles (VLPs) containing Vpr and Western blotting confirmed that Vpr down 179 
modulates REAF in MDMs and that Vpr alone is sufficient to induce this down modulation. 180 
We investigated the ability of Vpr to degrade REAF in MDMs early in infection. The 181 
subcellular fluctuations in REAF mean fluorescence intensity (MFI) were measured by imaging 182 
flow cytometry in large populations of target cells (>5000). In the presence of Vpr (HIV-1 89.6WT), 183 
nuclear REAF decreases within 2 hours of viral infection of macrophages from two donors (Figure 184 
2D), similar to that observed in HeLa-CD4 (Figure 1G). In contrast, also in both donors, nuclear 185 
REAF rapidly increases from as early as 0.5 hours when the virus does not contain Vpr (HIV-1 186 
89.6Δvpr) (Figure 2D). For the cytoplasmic compartment, a similar picture emerges for REAF 187 
fluctuation. In both donors, when Vpr is absent, REAF levels increase rapidly within 0.5 hours of 188 
infection (Figure 2D). This cytoplasmic increase is curtailed in donor 1 when Vpr is present. In 189 
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donor 2, the loss of nuclear REAF after HIV-1 89.6WT infection is paralleled by an increase in 190 
cytoplasmic REAF. Similar kinetics of total REAF protein fluctuation were measured by Western 191 
blotting in the presence or absence of Vpr in MDMs from two further donors (data not shown). 192 
We sought to determine if knockdown of REAF in primary macrophages results in an 193 
increase in susceptibility to HIV-1 infection. In Figure 2E, primary MDMs were treated with 194 
siRNA targeting REAF (siREAF) or a control protein (siCB). Cells lacking REAF were found to 195 
be significantly (p<0.0001) more susceptible to infection with HIV-1 89.6. We confirmed previous 196 
reports that HIV-1 replication in MDMs is more efficient in the presence of Vpr (27, 30). Figure 197 
2F shows that HIV-1 89.6Δvpr has restricted replication in MDMs compared with the wild type 198 
virus expressing Vpr (HIV-1 89.6WT).  199 
To investigate further the relationship between nuclear REAF and Vpr, we generated a 200 
virus with a substitution within Vpr (F34I). HIV-1 89.6F34I is incapable of localising to the nuclear 201 
membrane or of interacting with the nuclear transport protein importin-α and nucleoporins (30). 202 
Like HIV-1 89.6Δvpr, the mutant virus (HIV-1 89.6F34I) replicates less efficiently in MDMs (Figure 203 
2F). Using imaging flow cytometry, the respective abilities of these three viruses (HIV-1 89.6WT, 204 
89.6Δvpr and 89.6F34I)  in down modulating total REAF protein was investigated in MDMs (Figure 205 
2G). As expected, there is a loss of total REAF from 30 minutes after HIV-1 89.6WT infection 206 
(Figure 2G) with a transient recovery at around 2 hours. The opposite occurs in the absence of Vpr 207 
(HIV-1 89.6Δvpr) -, REAF levels increase after infection. The increase in REAF levels is most 208 
potent after 30 minutes of infection with HIV-1 89.6Δvpr.  HIV-1 89.6F34I, similar to HIV-1 89.6 209 
Δvpr can no longer deplete REAF in MDMs (Figure 2G).  210 
Other targets of Vpr have been reported. It recruits SLX4-SLX1/MUS81-EME1 211 
endonucleases to DCAF1, activating MUS81 degradation and triggering arrest in G2/M (33). It 212 
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also degrades helicase-like transcription factor (HLTF), a protein recently shown to enhance 213 
infection of HIV-1 in T-cell lines (8, 12). To determine if the depletion of REAF requires the 214 
association of Vpr with DCAF1, we generated another mutant virus with a different substitution 215 
within vpr, Q65R. Previously, the Q65R mutation was shown to ablate the association between 216 
DCAF1 and Vpr and the ability of Vpr to induce arrest at G2/M (34-36). Figures 2H and I show 217 
that this mutant, compared to HIV-1 89.6WT, is unable to down modulate REAF. We cannot rule 218 
out inhibition of synthesis or increased nuclear export in addition to degradation as possibilities.   219 
 220 
Expression of REAF during cell cycle 221 
 A phenotype of HIV-1 Vpr is that it can induce cell cycle arrest at G2/M in cycling T cells 222 
(27, 37-39). The failure of both HIV-1 89.6F34I and HIV-1 89.6Q65R to efficiently induce G2/M 223 
arrest (30, 34, 40-42), and our observation that they cannot down modulate REAF (Figures 2G, H 224 
and I), prompted us to investigate REAF and the cell cycle.  225 
First, we determined the expression levels of REAF at various phases of the cell cycle using 226 
imaging flow cytometry (Figure 3A). REAF protein levels are lowest in G0/1, increase through S 227 
phase, and peak in G2/M. Confocal microscopy of cycling cells concurred with the quantitative 228 
analysis in Figure 3A, overall REAF levels appeared greater in mitotic cells (Figure 3B). There is 229 
also an apparent exclusion of REAF from the nuclear region of the cell during mitosis (particularly 230 
during metaphase, anaphase and telophase). Quantitative analysis by imaging flow cytometry of 231 
cycling cells confirmed that the mitotic population had a lower nuclear enrichment score (0.13) 232 
compared to the non-mitotic cells (1.53), indicating a lower intensity of REAF in the nucleus 233 
compared to in the cell as a whole (Figure 3C). Representative images of subcellular REAF in 234 
mitotic and non-mitotic cells from imaging flow cytometry are presented in Figure 3D.  235 
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To determine if the G2/M arrest phenotype, induced by Vpr, could be related to its ability 236 
to down modulate REAF, we generated inducible THP-1 and PM1 cell lines that upon induction 237 
produce shRNA targeting either REAF or a scrambled control sequence (SCR). After knockdown 238 
of REAF in THP-1, there was a clear increase in the expression of the mitotic marker, 239 
phosphorylated histone H3 (Ser10/Thr11) (Figure 3E). However, when measured more 240 
quantitatively by DNA content analysis in PM1, the potency of the G2/M arrest appeared weak 241 
compared to the levels previously described (30, 39). REAF down modulation in PM1 was 242 
confirmed by a reduction in mRNA and in protein (Figure 3F and G). Cell cycle phase profiles 243 
were determined by flow cytometry (Figure 3H). The increase in the G2/G1 ratio of cells with 244 
REAF knocked down, although small (Figure 3H, insert), was comparable to other reports where 245 
individual reported targets of Vpr were knocked down (14). In agreement with Greenwood et al. 246 
2019, we contend that more than one protein may be required to produce the strong Vpr induced 247 
G2/M arrest reported (14, 30, 39).   248 
 249 
REAF is not IFN stimulated or under positive selection. 250 
IFNα is central to innate immune responses and is known to induce many HIV-1 restriction 251 
factors (43, 44). We used RNA microarray analysis to determine if IFNα upregulated REAF 252 
mRNA in MDMs. Figure 4A shows that IFNα induced upregulation of many known antiviral 253 
genes, including HIV restriction factors APOBEC3G, MX2, Tetherin and Viperin (45)(46)(43) 254 
but with little or no upregulation of REAF mRNA. Nevertheless, antiviral factors are also often 255 
upregulated in response to pathogen associated molecular patterns (PAMPs). Poly(I:C) is a double-256 
stranded RNA, used to stimulate molecular pattern recognition pathways associated with viral 257 
infection. Figure 4B shows that poly(I:C) induces REAF in THP-1, a macrophage cell line. 258 
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Lipopolysaccharide (LPS), another PAMP which is TLR4 specific (47), also induces the 259 
upregulation of REAF expression in PBMCs (Figure 4C). 260 
Restriction factors are often under evolutionary positive selection at sites that interact with 261 
virus. We compared REAF DNA sequences from 15 extant primate species using PAML package 262 
for signatures of positive natural selection. We found no evidence of positive selection of REAF 263 




















The deletion of vpr in HIV-1 leads to impairment of its replication in both HeLa-CD4 and 282 
primary macrophages. A number of experiments presented here point to a role for Vpr in the 283 
counter-restriction of the antiviral protein REAF. First, HIV-1 replication is significantly enhanced 284 
by knockdown of REAF in either HeLa-CD4 or primary macrophages and this phenotype is more 285 
pronounced for viruses lacking vpr. Second, REAF is down modulated early after infection in a 286 
manner dependent on both the presence of Vpr and, as demonstrated by vpr single point mutations, 287 
the localization of Vpr to the nuclear envelope and its interaction with a nuclear localised E3 288 
ubiquitin ligase, DCAF1. Third, using VLPs we show that Vpr alone is sufficient to down 289 
modulate REAF in MDMs. Finally, by co-immunoprecipitation, we demonstrate that REAF and 290 
Vpr physically interact, either directly, or indirectly as part of a complex. Taken together, our 291 
results highlight the importance of the relationship between REAF and the HIV-1 accessory 292 
protein Vpr. 293 
Others have shown a specific requirement for Vpr in the efficient infection of non-dividing 294 
cells and less so in cycling T cells (12, 27, 30). The requirement for Vpr in macrophage infection 295 
is substantiated here, reduced viral replication is observed after infection of MDMs with either 296 
HIV-1 89.6∆vpr or HIV-1 89.6F34I compared to HIV-1 89.6WT. This is the first demonstration of a 297 
vpr-alleviated impairment of HIV-1 replication in primary macrophages. Recently Yan et al. 298 
(2019) show that HLTF, a reported target of Vpr, restricts replication of HIV-1 in T cells while 299 
Lahouassa et al. (2016) also reported a Vpr dependent loss of HLTF at six hours post- infection 300 
(8, 12). HLTF down modulation occurs concomitantly with REAF as early as 0.5 hours post- 301 
infection (data not shown). Interestingly, HLTF and REAF were identified in the same screen for 302 
proteins that interact with single-stranded DNA (48).  303 
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The transient nature and timing of REAF depletion shown here is consistent with its ability 304 
to impede the production of reverse transcripts early in infection (20). After an initial down 305 
modulation of REAF following infection, REAF depletion is paused, perhaps attributable to the 306 
limited quantities of Vpr carried in the virus particle (17). Recently, Greenwood et al. carried out 307 
a whole cell proteomics screen for factors up or down modulated by Vpr in T cells. They identified 308 
almost 2000 proteins affected, underlining the promiscuous activity of Vpr (14). In light of these 309 
findings, it is important that attention is directed to those reported Vpr targets that affect replication 310 
of HIV-1 in primary cells. 311 
Our model is that Vpr is carried into the cell by HIV-1, in limited, but sufficient quantities 312 
to down modulate REAF in the timeframe required for reverse transcription to proceed unhindered. 313 
Interestingly, nuclear localisation of Vpr is also required for the down modulation of REAF, 314 
perhaps similar to the Vpx mediated depletion of the reverse transcription inhibitor SAMHD1 (for 315 
which degradation is initiated in the nucleus) (49). Localisation of Vpr to the nuclear region is a 316 
requirement for interaction with REAF and DCAF1 and this results in the degradation of REAF. 317 
We propose that REAF is linked to the innate immune response as treatment of cells with poly(I:C) 318 
or LPS induces its expression. Furthermore, HIV-1 replication without an intact vpr, induces the 319 
expression of REAF to high levels in primary macrophages as early as 30 minutes post- infection. 320 
A poorly understood event is that Vpr induces cell cycle arrest in the G2/M phase after 321 
infection. We report here that the loss of REAF from cycling cells contributes to an accumulation 322 
of the population in G2/M. However, the levels of G2/M induction are weak compared to early 323 
reports (30, 39).  Thus , we contend that Vpr-induced knock down of more than one protein by 324 
Vpr may be required for the complete induction of G2/M arrest seen previously. In support of this, 325 
G2/M arrest was only weakly induced when Greenwood et al. independently knocked down 326 
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several Vpr targeted proteins such as MCM10, SMN1, CDCA2 and ZNF267 (14). 327 
REAF is unlike the evolving HIV restriction factors such as APOBEC3G, SAMHD1, 328 
TRIM5 or BST2/Tetherin and is more similar to SERINC3 and 5 which are not under positive 329 
selection (50, 51). REAF has many properties of restriction factors (45, 52). It interacts with HIV-330 
1 reverse transcripts, impeding reverse transcription (20). It is germline encoded, constitutively 331 
expressed in cells, regulated by the proteasome system, suppressed by an accessory protein, Vpr, 332 
and upregulated by poly(I:C) and LPS. Our results support the current model for Vpr activity which 333 
is that it induces the degradation of proteins involved in an unknown restriction of HIV-1. We 334 
propose that REAF may be a crucial component a Vpr targeted restriction system that is active 335 














Materials and Methods 348 
Ethics Statement 349 
Leucocyte cones, from which PBMCs were isolated, were obtained from the NHS Blood 350 
Transfusion service at St. George’s Hospital, London. Donors were anonymous and thus patient 351 
consent was not required. The local ethical approval reference number is 06/Q0603/59. 352 
  353 
Cell Lines 354 
HEK-293T (ATCC), PM1, THP-1, C8166, HeLa-CD4 (all NIBSC AIDS Reagents) and 355 
HeLa-CD4 shRNA-REAF (previously described) (18) were maintained at 37°C in 5% CO2. Cells 356 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Thermo Fisher) supplemented 357 
with fetal bovine serum (FBS) 5-10% and appropriate antibiotics (all Thermo Fisher). HeLa-CD4-358 
shRNA-REAF were selected for resistance to puromycin in media supplemented with 10µg/ml 359 
puromycin (Invitrogen). 360 
The isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible vector pLKO-IPTG-3xLacO 361 
(Sigma) was used to express short hairpin RNAs (shRNAs) targeted against REAF (Mission 362 
TRCN0000141116, Sigma). Additionally, a non-target (scramble) control was prepared. Viral 363 
particles for cell line transductions were prepared by co-transfecting HEK-293T cells with pLKO-364 
IPTG-3xLacO, the Gag/Pol packaging vector pLP1, a Rev expression vector pLP2, and the 365 
vesicular stomatitis virus G protein (VSV-G) expression vector pVPack-VSV-G (Stratagene). 366 
After 72 hours, virus was clarified by low-speed centrifugation and passed through a 0.45-m-pore-367 
size filter. THP-1 and PM1 cells were transduced by culturing viral particles in the presence of 368 
8g/ml Polybrene for 72 hours, after which resistant colonies were selected and maintained with 369 
2µg/ml puromycin. Culturing cells in the presence of 1mM IPTG for 72 hours induced expression 370 
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of shRNAs. 371 
 372 
Transfections and Virus/VLP Production 373 
The infectious molecular clone for HIV-1 89.6 was obtained from the Centre for AIDS 374 
Research (NIBSC, UK). Infectious full-length and chimeric HIV clones were prepared by linear 375 
polyethylenimine 25K (Polysciences), Lipofectamine 2000 (Invitrogen) or Lipofectamine 3000 376 
(Invitrogen) transfection of HEK-293T. Virus-like particles (VLPs) were produced by linear 377 
polyethylenimine 25K (Polysciences) transfection of HEK-293T. The VLP packaging vector was 378 
a gift from N. Landau and production is described in reference (27).  379 
The plasmid construct HIV-1 89.6Δvpr was generated from the HIV-1 89.6 molecular clone, 380 
using overlap extension PCR (44). Clones were confirmed by plasmid sequencing (Source 381 
BioScience). Primer sequences are available upon request. HIV-1 p89.6 vpr mutants F34I and 382 
Q65R were made by site directed mutagenesis (Agilent) of the p89.6 plasmid. HEK-293T were 383 
plated at 2x104/cm2 in 10cm dishes (for virus and VLP production) 48 hours prior to transfection. 384 
For virus/VLP production, supernatant was harvested 72 hours post- transfection and cleared of 385 
cell debris by centrifugation at 500 x g for 5 minutes. All viruses were amplified by C8166 for 48 386 
hours prior to harvest. 387 
 
388 
Titration of Replication Competent Virus 389 
HeLa-CD4 were seeded at 1.5×104 cells/well in 48-well plates to form an adherent 390 
monolayer of cells. Cell monolayers were challenged with serial 1/5 dilutions of virus and titre 391 
was assessed after 48 hours by in situ intracellular staining of HIV-1 p24 to identify individual 392 
foci of viral replication (FFU), as described previously (53). For infection time course experiments, 393 
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400-500μl of 1×105 FFU/ml (HeLa-CD4) or 3×103 FFU/ml (MDMs) virus was added per well to 394 
cells cultured in 6-well trays for 24 hours (HeLa-CD4) or 7 days (for MDMs). For Figure 2F and 395 
2H, cells were challenged with 50ng p24 in 6-well plates with 2×106 MDMs per well. For Figure 396 
2F, supernatants were harvested on days 0, 2, 8, 21 and 28 post- challenge and p24 concentration 397 
analysed by ELISA. 398 
 399 
p24 ELISA 400 
ELISA plates were pre-coated with 5μg/ml sheep anti-HIV-1 p24 antibody (Aalto Bio 401 
Reagents) at 4°C overnight. Viral supernatants were treated with 1% Empigen® BB for 30 minutes 402 
at 56°C, then plated at 1:10 dilution in tris-bufered saline (TBS) on pre-coated plates and incubated 403 
for 3 hours at room temperature. Alkaline phosphatase-conjugated mouse anti-HIV-1 p24 404 
monoclonal antibody (Aalto Bio Reagents) in TBS 20% sheep serum, 0.05% v/v Tween-20 was 405 
then added and incubated for 1 hour at room temperature. After 4 washes with PBS 0.01% v/v 406 
Tween-20 and 2 washes with ELISA Light washing buffer (ThermoFisher), CSPD substrate with 407 
Sapphire II enhancer (ThermoFisher) was added and incubated for 30 minutes at room temperature 408 
before chemiluminescence detection using a a plate reader. 409 
 410 
cDNA Synthesis and qPCR  411 
Total RNA was extracted from PM1 cells using the ReliaPrep RNA Kit (Promega). One-412 
step reverse transcription qPCR (Quantbio) using TaqMan probes detected amplified transcripts. 413 
Data acquired by an Agilent Mx3000 was analyzed with MxPro software.  414 
 415 
Gene Expression RNA microarray 416 
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Prior to microarray analysis, RNA from MDMs was prepared using the Illumina™ 417 
TotalPrep™ RNA Amplification Kit (Ambion), according to manufacturer’s instructions. The 418 
probes were hybridized on an Illumina™ HT12v3 bead array following the manufacturer’s standard 419 
hybridization and scanning protocols. Raw measurements were processed by GenomeStudio 420 
software (Illumina), and quantile normalized. Microarray data are publicly available in the Gene 421 
Expression Omnibus (GEO) database with accession number GSE54455. 422 
 423 
IFN, Poly(I:C) and LPS Treatment 424 
MDMs were treated with IFN (500IU/ml) for 24 hours before harvest for RNA extraction. 425 
Recombinant IFNα was purchased from Sigma (Interferon-αA/D human Cat. No. I4401-100KU) 426 
and is a combination of human subtypes 1 and 2. THP-1 were treated with poly(I:C) (25μg/ml, 427 
HMW/LyoVec™, Invitrogen) for 48 hours before analysis by Western blotting. Prior to poly(I:C) 428 
treatment, THP-1 were treated with phorbol 12-myristate 13-acetate (PMA, 62ng/ml) for 3 days 429 
and then PMA-free DMEM for 2 days to allow differentiation and recovery. PBMCs isolated from 430 
healthy blood donors were treated with lipopolysaccharide (LPS, 10 ng/ml) for 24 hours before 431 
analysis by Western blotting. 432 
 433 
Western blotting 434 
Cells were harvested and lysed in 30-50μl of radioimmunoprecipitation assay (RIPA) 435 
buffer supplemented with NaF (5µM), Na2VO3 (5µM), β-glycerophosphate (5µM) and 1x Protease 436 
Inhibitor Cocktail (Cytoskeleton). The protein concentration of each sample was determined using 437 
BCA Protein Assay Kit (Pierce). 12.5-70µg of total protein was separated by SDS-PAGE (4-12% 438 
Bis-Tris Gels, Invitrogen), at 120V for 1 hour 45 minutes in MOPS SDS Running Buffer 439 
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(Invitrogen). Separated proteins were transferred onto nitrocellulose membrane (0.45μm pore size, 440 
GE Healthcare) at 45V for 2 hours, in ice-cold 20% (v/v) Methanol NuPAGE™ Transfer Buffer 441 
(ThermoFisher). After transfer, membranes were stained for total protein using Ponceau S staining 442 
solution (0.1% (w/v) Ponceau in 5% (v/v) acetic acid), washed 3 times for 5 minutes on an orbital 443 
shaker in dH2O and imaged using ChemiDoc Gel Imaging System. Membranes were blocked for 444 
1 hour at room temperature in 5% (w/v) non-fat milk powder in TBS-T buffer. Specific proteins 445 
were detected with primary antibodies by incubation with membranes overnight at 4⁰C and with 446 
secondary antibodies for 1 hour at room temperature. All antibodies were diluted in blocking 447 
buffer. Proteins were visualized using ECL Prime Western Blotting Detection Reagent (GE 448 
Healthcare) and imaged using either ChemiDoc Gel Imaging System (Bio-Rad) or exposed to CL-449 
XPosure films (ThermoScientific) and developed. In all places where quantitative comparisons are 450 
made, such as in Figures 1D and E, blots are derived from the same blot or blots processed together. 451 
 452 
Antibodies 453 
Primary rabbit polyclonal antibody to REAF (RbpAb-RPRD2) has been previously 454 
described (20). For imaging flow cytometry and confocal microscopy, RbpAb-RPRD2 was 455 
detected using goat anti-rabbit IgG conjugated with Alexa Fluor 647 (Invitrogen). FITC-labelled 456 
anti-phospho-histone H3 (Ser28) Alexa 488 was used (BD Bioscience) for imaging flow cytometry 457 
and confocal microscopy. MsmAb-GFP (both Abcam) was detected by anti-mouse IgG antibody 458 
conjugated to HRP (GE Healthcare) for Western blotting. Also for Western blotting, RbpAb-459 
RPRD2, RbmAb-IFITM3 (EPR5242, Insight Biotechnology), RbpAb-GAPDH, and RbmAb-460 
phospho-histone H3 (Ser10/Thr11) were detected with donkey anti-rabbit IgG conjugated to HRP 461 





HEK-293T, transfected with either Vpr-GFP expression plasmid or GFP control 465 
expression vector, were lysed 72 hourshrs post- transfection in RIPA buffer supplemented with 466 
NaF (5µM), Na2VO3 (5µM), β-glycerophosphate (5µM) and 1x Protease Inhibitor Cocktail 467 
(Cytoskeleton). Total protein concentration was determined using BCA Protein Assay Kit (Pierce). 468 
GFP-TRAP® magnetic agarose beads were equilibrated in ice cold dilution buffer (10 mM Tris/Cl 469 
pH 7.5; 150 mM NaCl; 0.5 mM EDTA) according to manufacturer’s instructions (Chromotek). 470 
Cell lysates containing 100µg of total protein were incubated with 10µl of equilibrated beads for 471 
2 hours at 4⁰C with gentle agitation. Beads were washed three times with PBST buffer before 472 
analysis of immunoprecipitated protein by Western blotting. 473 
 474 
Magnetic Separation of Primary Human Lymphocytes 475 
Peripheral blood mononuclear cells (PBMCs) were isolated from leukocyte cones (NHS 476 
Blood Transfusion service, St. George’s Hospital, London) by density gradient centrifugation with 477 
Lymphoprep™ density gradient medium (STEMCELL™ Technologies). Peripheral monocytes 478 
were isolated from PBMCs, using the human CD14+ magnetic beads (Miltenyi Biotech) according 479 
to manufacturer’s instructions. CD4+ T cells were isolated from the flow-through, using the human 480 
CD4+ T cell isolation kit (Miltenyi Biotech). CD14+ monocytes, and CD4+ T cells were either 481 
differentiated, or fixed directly after isolation for intracellular staining. To obtain M1 and M2 482 
macrophages (M1/M2 MDMs), monocytes were treated with either granulocyte-macrophage 483 
colony stimulating factor (GM-CSF, 100ng/ml, Peprotech) or macrophage colony stimulating 484 
factor (M-CSF, 100ng/ml) for 7 days, with medium replenished on day 4. To obtain dendritic cells 485 
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(DC), monocytes were treated with GM-CSF (50ng/ml) and IL-4 (50ng/ml) for 7 days, with 486 
medium replenished on day 4. Activated CD4+ T cells were obtained by stimulating freshly 487 
isolated CD4+ T cells at 1x106/ml with T cell activator CD3/CD28 Dynabeads (ThermoFisher), at 488 
a bead-cell-ratio of 1, for 7 days. Magnetic beads were removed prior to intracellular staining and 489 
imaging flow cytometry. 490 
 491 
Immunofluorescence 492 
HeLa-CD4 were plated at 2x104/cm2 in 8-well chamber slides for confocal microscopy. 493 
Cells were washed with PBS, fixed in 2% paraformaldehyde/PBS for 10 minutes at room 494 
temperature. Fixed cells were permeabilized in 0.2% Triton™-X100/PBS for 20 minutes at room 495 
temperature and incubated with primary antibodies in PBS 0.1% Triton-X100 2% BSA overnight 496 
at 4⁰C. After 3 washes in PBS, cells were labelled with secondary antibodies in the same buffer 497 
for 1 hour at room temperature, and washed 3 times with PBS. Nuclei were counterstained with 498 
Hoechst 33342 (2µM, ThermoFisher) for 5 minutes at room temperature. Labelled cells were 499 
mounted with ProLong™ Diamond Antifade Mountant (ThermoFisher) and analyzed on a laser 500 
scanning confocal microscope LSM 710 (Carl Zeiss). Images were acquired with ZEN software 501 
and analyzed with ImageJ. 502 
 503 
Imaging Flow Cytometry  504 
Cells were fixed in FIX&PERM® Solution A (Nordic MUbio) for 30 minutes, and 505 
permeabilized with 0.2% Triton™-X 100/PBS. MDMs were blocked with human serum (1%). The 506 
staining buffer used was: 0.1% Triton™-X 100 0.5% FBS. Nuclei were counterstained with DAPI 507 
(1µg/ml) for two hours. Imaging flow cytometry was performed using the Amnis ImageStream®x 508 
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Mark II Flow Cytometer (Merck) and INSPIRE® software (Amnis). A minimum of 5000 events 509 
were collected for each sample. IDEAS® software (Amnis) was used for analysis and to determine 510 
the ‘nuclear enrichment score’ (NES). The NES is a comparison of the intensity of REAF 511 
fluorescence inside the nucleus (defined using the exclusively nuclear stain DAPI) to the total 512 
fluorescence intensity of REAF in the entire cell (defined using brightfield images). A lower 513 




Statistical significance in all experiments was calculated by Student’s t-test (two tailed) or 518 
ANOVA (indicated). Data are represented as mean ± standard deviation (error bars). GraphPad 519 
Prism and Excel were used for calculation and illustration of graphs.  520 
 521 
Cell Cycle Analysis  522 
Cell cycle phase distribution was determined by analysis of DNA content via either flow 523 
cytometry (BD FACS Canto™ II) or imaging flow cytometry. Cells were fixed in FIX&PERM® 524 
Solution A (Nordic MUbio) and stained with DAPI (1µg/ml) before analysis by imaging flow 525 
cytometry. Cell lysates were assessed by Western blotting using the anti-phospho-histone H3 526 
(Ser10/Thr11) antibody as an additional mitotic marker. Chromatin morphology and anti-phospho-527 
histone H3 (Ser28) were used to determine the cells in indicated phases of the cell cycle and mitosis 528 
in confocal microscopy experiments. Cell cycle status of PM1 cells was determined via propidium 529 
iodide (PI) staining using FxCycle PI/RNse solution (ThermoFisher). Stained cells were analyzed 530 




Evolutionary Analysis 533 
To ascertain the evolutionary trajectory of REAF, we analyzed DNA sequence alignments 534 
of REAF from 15 species of extant primates using codeml (as implemented by PAML 4.2) (54). 535 
The evolution of REAF was compared to several NSsites models of selection, M1, M7 and M8a 536 
(neutral models with site classes of dN/dS <1 or 1) and M2, M8 (positive selection models 537 
allowing an additional site class with dN/dS >1). Two models of codon frequencies (F61 and F3x4) 538 
and two different seed values for dN/dS (ω) were used in the maximum likelihood simulations. 539 
Likelihood ratio tests were performed to evaluate which model of evolution the data fit 540 
significantly better. The p-value indicates the confidence with which the null model (M1, M7, 541 
M8a) can be rejected in favor of the model of positive selection (M2, M8). The alignment of REAF 542 
was analyzed by GARD to confirm the lack recombination during REAF evolution (55). Neither 543 
positively selected sites nor signatures of episodic diversifying selection were detected within 544 
REAF by additional evolutionary analysis by REL and FEL or MEME (56). 545 
 546 
Data Availability 547 
All RNA microarray data is available in the gene expression omnibus (GEO) database with 548 
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Figure 1: HIV-1 Vpr interacts with REAF and overcomes restriction. (A) REAF protein in 758 
HeLa-CD4 (Ø) and HeLa-CD4 shRNA-REAF (shREAF). GAPDH is a loading control. (B) 759 
Infectivity (FFU/ml) of HIV-1 89.6WT and HIV-1 89.6∆vpr in HeLa-CD4 (Ø) and HeLa-CD4 760 
shRNA-REAF (shREAF). Viral inputs were equivalent at approximately 50 FFU/ml measured on 761 
HeLa-CD4. Error bars in indicate the standard deviations of means derived from a range of 762 
duplicate titrations. Fold changes in FFU are indicated. (C) Resulting foci of infection from equal 763 
p24 inputs (1ng) of HIV-1 89.6WT or HIV-1 89.6∆vpr in HeLa-CD4. Error bars in indicate the 764 
standard deviations of means derived from a range of duplicate titrations. (D) REAF protein in 765 
Hela-CD4 24 hours post- challenge with HIV-1 89.6WT or HIV-1 89.6Δvpr. GAPDH is a loading 766 
control. (E) HEK-293T cells were transfected with Vpr-GFP expression plasmid or GFP control 767 
vector, expression was analysed by Western blotting (left) and protein was immunoprecipitated 768 
(IP) with anti-GFP beads. Co-immunoprecipitated REAF was detected in the Vpr-GFP 769 
precipitation (right). (F) Nuclear and cytoplasmic REAF mean fluorescence intensity (MFI) in 770 
HeLa-CD4 measured by imaging flow cytometry. Error bars represent standard deviations of 771 
means of replicates. (G) Percentage (%) change in REAF MFI from time ‘0’ in the nucleus (left) 772 
and cytoplasm (right) of Hela-CD4 over time after challenge with HIV-1 89.6WT or HIV-1 89.6∆vpr. 773 
Results are representative of three independent experiments. (H) Nuclear enrichment score of 774 
HeLa-CD4 over time post- challenge with HIV-1 89.6WT or HIV-1 89.6∆vpr. A lower nuclear 775 
enrichment score indicates a lower proportion of overall REAF is located in the nucleus as 776 
calculated by IDEAS software. Results are representative of three independent experiments. 777 









Figure 2: Fluctuations in subcellular REAF expression after HIV-1 infection are Vpr 783 
dependent. (A) Nuclear and cytoplasmic REAF mean fluorescence intensity (MFI) in MDMs 784 
measured by imaging flow cytometry. Error bars represent standard deviations of means of 785 
replicates. (B) Nuclear REAF MFI in indicated primary cell types measured by imaging flow 786 
cytometry. Error bars represent standard deviations of means of two blood donors. (C) REAF 787 
protein in MDMs treated with empty or Vpr-containing VLPs. GAPDH is a loading control. VLP 788 
input was equivalent at 100ng of p24. (D) Percentage (%) change in subcellular REAF MFI in 789 
MDMs from time ‘0’ measured by imaging flow cytometry after challenge with HIV-1 89.6WT or 790 
HIV-1 89.6∆vpr. Data from two donors are presented. (E) Infectivity (FFU/ml) of HIV-1 89.6WT in 791 
MDMs transfected with siRNA-REAF. HiPerfect (transfection reagent) and siCB are negative 792 
controls. ** = P<0.01, ns = not significant, one-way ANOVA and post hoc Dunnett’s test. (F) 793 
Infectivity of HIV-1 89.6WT compared with HIV-1 89.6Δvpr and HIV-1 89.6 F34I in MDMs. p24 794 
antigen concentrations over 28 days post- infection are indicated. Viral input was equivalent at 795 
50ng of p24. Error bars represent standard deviations of means of duplicates (*** = P < 0.001; 796 
**** = P < 0.0001, two-way ANOVA; the same results were obtained for HIV-1 89.6WT versus 797 
HIV-1 89.6Δvpr and HIV-1 89.6 F34I). Data is representative of at least two independent 798 
experiments. (G) Percentage (%) change in total cellular REAF MFI from time ‘0’ in MDMs after 799 
challenge with HIV-1 89.6WT, HIV-1 89.6∆vpr or HIV-1 89.6F34I. Results are representative of three 800 
independent experiments. (H) REAF protein, measured by Western blotting, in MDMs challenged 801 
with HIV-1 89.6WT or HIV-1 89.6Q65R over time. Ponceau S staining of nitrocellulose membrane 802 
is a loading control. Associated densitometry is presented in (I) where error bars represent standard 803 








Figure 3: Depletion of REAF results in G2/M accumulation (A) Imaging flow cytometry of 808 
cell cycle phase and REAF protein in DAPI stained primary monocytes (B) Confocal microscopy 809 
of subcellular REAF in HeLa-CD4. Phospho-histone H3 (Ser28) staining and chromatin 810 
morphology (Hoechst 33342) were used for cell cycle phase identification. (C) Imaging flow 811 
cytometry of subcellular REAF in cycling HeLa-CD4. A lower nuclear enrichment score (red) 812 
indicates a lower proportion of overall REAF in the nucleus. Phospho-histone H3 (Ser28) staining 813 
confirmed mitotic cells had a lower score of 0.13. (D) Representative images of subcellular REAF 814 
in mitotic and non-mitotic cells. (E) REAF protein in THP-1 with IPTG-inducible shRNA 815 
targeting REAF (shREAF) or a scrambled control sequence (shSCR). Phospho-histone H3 816 
(Ser10/Thr11) is a mitotic marker and GAPDH is a loading control. (F) Fold change in mRNA 817 
transcript level in PM1 shREAF normalized to PM1 shSCR measured by qPCR (G) REAF protein 818 
in PM1 expressing shRNA targeting REAF (shREAF) and PM1 expressing a scrambled control 819 
sequence (shSCR). GAPDH is a loading control. (H) Flow cytometry of cell cycle phase in PI 820 
stained PM1 shREAF (black outline) and PM1 shSCR (grey outline). Plot shown is representative 821 
of three biological replicates. Insert shows fold change in G2/G1 ratio in PM1 shREAF normalized 822 













Figure 4: REAF is not IFN stimulated or under positive selection. (A) RNA microarray 832 
determined change in REAF mRNA compared to other antiviral factors in MDMs treated with 833 
IFNα (500IU/ml). (B) REAF protein in PMA differentiated THP-1 after poly(I:C) treatment for 834 
48 hours. GAPDH is a loading control. (C) REAF protein in PBMCs after LPS treatment. GAPDH 835 
is a loading control and IFITM3 is a positive control for LPS induced upregulation. (D) REAF 836 
DNA sequences from 15 extant primate species (tree length of 0.2 substitutions per site along all 837 
branches of the phylogeny) (top) were analyzed using the PAML package for signatures of positive 838 
natural selection (bottom). Initial seed values for ω (ωO) and different codon frequency models 839 
were used in the maximum likelihood simulation. Twice the difference in the natural logs of the 840 
likelihoods (2*InL) of the two models were calculated and evaluated using the chi-squared critical 841 
value. The p value indicates the confidence with which the null model (M1, M7, M8a) can be 842 
rejected in favor of the model of positive selection (M2, M8). 843 
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